Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

US88023B1035
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG01MZQYJF9
TEM
Tempus AI, Inc.
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: - · THEMEFOLIO: $BBLL
NAME
Tempus AI, Inc.
ISIN
US88023B1035
TICKER
TEM
MIC
XNAS
REUTERS
TEM.OQ
BLOOMBERG
TEM US
Mon, 12.01.2026       Tempus AI
US88023B1035

Tempus, a leader in artificial intelligence and precision medicine, and NYU Langone Health, one of the nation’s premier academic medical centers, today announced a multi-year strategic collaboration aimed at transforming cancer care through advanced molecular profiling and data-driven insights. The collaboration will support NYU Langone Health’s C...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Mon, 12.01.2026       Tempus AI
US88023B1035

Northwestern Medicine and Tempus AI, Inc. (NASDAQ: TEM) are collaborating to expand access to genomic testing for Northwestern Medicine cancer patients. The goal is to provide nearly every patient across cancer types, including patients with early-stage cancer diagnoses, access to genomic testing. Patients will benefit from a deeper understanding...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Sun, 11.01.2026       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a record Total Contract Value (TCV) of >$1.1 billion as of December 31, 2025. During 2025, Tempus signed data agreements with over 70 customers, spanning both large and mid-sized pharma, including AstraZeneca, GlaxoSmith...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Sun, 11.01.2026       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced select, preliminary, unaudited results for the fourth quarter and full year ended December 31, 2025. Full Year 2025 Select, Preliminary, Unaudited Financial Results Revenue of ~$1.27 billion, representing ~83% growth y...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Thu, 08.01.2026       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that eight abstracts have been accepted for presentation at the 2026 ASCO® Gastrointestinal Cancers Symposium. The meeting is being held on January 8–10 in San Francisco, California. “The research Tempus is presenting at...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Tue, 06.01.2026       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, will participate in the 44th Annual J.P. Morgan Healthcare Conference, taking place January 12-15, 2026, in San Francisco, California. Tempus Founder and CEO Eric Lefkofsky will deliver a presentation, followed by a live Q&A session,...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Tue, 09.12.2025       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that ten abstracts have been accepted for presentation at the 2025 San Antonio Breast Cancer Symposium (SABCS). The meeting takes place December 9–12 at the Henry B. González Convention Center in San Antonio, Texas. “This...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Tue, 18.11.2025       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced that it will participate in the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3rd in New York City. Jim Rogers, Chief Financial Officer at Tempus, will participate in a fireside chat at 10:30 AM ET. The live webcast...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Fri, 14.11.2025       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a new research study sponsored by Tempus and being run in collaboration with the Institute for Follicular Lymphoma Innovation (IFLI), a global, nonprofit, private foundation dedicated to accelerating the development of inno...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Wed, 05.11.2025       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that six abstracts have been accepted for presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025. The meeting is taking place November 5 - 9 at the Gaylord National Convention Center in National...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Tue, 04.11.2025       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter ended September 30, 2025. Revenue grew 84.7% year-over-year to $334.2 million in the third quarter of 2025 Gross profit reached $209.9 million in the third quarter of 20...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Tue, 28.10.2025       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced that it will participate in the Stifel 2025 Healthcare Conference on Thursday, November 13 in New York City. Jim Rogers, Chief Financial Officer at Tempus, will participate in a fireside chat at 10:00 AM ET. The live webcast will be availab...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Tue, 21.10.2025       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the third quarter of 2025 on November 4, 2025. The company will hold the earnings conference call at 4:30 pm ET. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Office...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Mon, 20.10.2025       Tempus AI
US88023B1035

Ambry Genetics, a leader in genetic testing, and a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), announced the publication of a peer-reviewed study in Genetics in Medicine (GIM), the official journal of the American College of Medical Genetics and Genomics (ACMG). The ACMG is a national organization bringing together experts in medical...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Thu, 16.10.2025       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a multi-year collaboration with Whitehawk Therapeutics, Inc. (NASDAQ: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjuga...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Wed, 15.10.2025       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that six abstracts have been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2025, taking place October 17–21 in Berlin, Germany. “We’re sharing research at ESMO Congress 2025, inclu...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Thu, 09.10.2025       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced it has been selected by the Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services, to provide testing and contract research organization (CRO) services in s...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Wed, 01.10.2025       Tempus AI
US88023B1035

Ambry Genetics, now a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM) and a pioneer in clinical genomic testing, today announced an enhancement to the Ambry CARE Program® (CARE), Ambry’s digital platform that streamlines cancer risk assessment and genetic testing workflows. The update integrates breast density into the Tyrer-Cuzick (TC) b...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Mon, 22.09.2025       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its RNA-based Tempus xR IVD device. xR IVD will be offered as a life sciences tool to support drug development programs....
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Fri, 19.09.2025       Tempus AI
US88023B1035

NEW YORK, Sept. 19, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Tempus AI, Inc. (NASDAQ: TEM) breached their fiduciary duties to shareholders. ...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Thu, 11.09.2025       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its updated Tempus Pixel, an AI-powered cardiac imaging platform. This update allows the generation of T1 and T2 inline maps, further enh...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Tue, 09.09.2025       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the publication of a study in JCO Precision Oncology validating the clinical utility of the company’s PurIST® algorithmic diagnostic. The study provides the largest real-world evidence to date supporting the integration of...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Thu, 04.09.2025       Tempus AI
US88023B1035

Northwestern Medicine and Tempus AI, Inc. (NASDAQ: TEM) today announced a notable expansion of their longstanding collaboration. Northwestern Medicine will be the first health system to integrate David, Tempus’ generative-AI clinical co-pilot, within its electronic health record (EHR) platform for its clinical care team. The expanded collaboration...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Wed, 03.09.2025       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in Morgan Stanley’s 23rd Annual Global Healthcare Conference. The conference will take place September 8-10 in New York City. Eric Lefkofsky, Founder and CEO of Tempus, and Jim Rogers, Chief Financial Offi...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Fri, 22.08.2025       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the acquisition of Paige, an AI company specializing in digital pathology. The acquisition allows Tempus to grow its dataset, expand its experienced technical team, and establish a strong footprint in digital pathology with...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Mon, 11.08.2025       Tempus AI
US88023B1035

NEW YORK, Aug. 11, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Tempus AI, Inc. ("Tempus" or the "Company")(NASDAQ: TEM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encoura...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Mon, 11.08.2025       Tempus AI
US88023B1035

LOS ANGELES, Aug. 11, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Tempus AI, Inc. ("Tempus" or "the Company") (NASDAQ: TEM) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Se...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Thu, 07.08.2025       Tempus AI
US88023B1035

News provided by DJS Law Group LLP  LOS ANGELES, Aug. 7, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Tempus AI, Inc. ("Tempus" or "the Company") (NASDAQ: TEM) for violations of securities laws. Shareholders who purchased the Company's securities between August 6, 2024, and May 27, 2025, inclusive (t...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Thu, 07.08.2025       Tempus AI
US88023B1035

LOS ANGELES, Aug. 7, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Tempus AI, Inc. ("Tempus" or "the Company") (NASDAQ: TEM) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Sec...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Sat, 02.08.2025       Tempus AI
US88023B1035

NEW YORK and NEW ORLEANS, Aug. 1, 2025 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 12, 2025 to file lead plaintiff applications in a securities class action lawsuit against Tempus AI, Inc. (NasdaqGS: TEM), if they purch...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Thu, 31.07.2025       Tempus AI
US88023B1035

LOS ANGELES, July 31, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Tempus AI, Inc. ("Tempus" or the "Company") (NASDAQ: TEM) have opportunity to lead the securities fraud class action lawsuit....
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Thu, 31.07.2025       Tempus AI
US88023B1035

LOS ANGELES, July 31, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Tempus AI, Inc. ("Tempus" or "the Company") (NASDAQ: TEM) for violations of securities laws. Shareholders who purchased the Company's securities between August 6, 2024, and May 27, 2025, inclusive (the "Class Period"), are encouraged...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Thu, 31.07.2025       Tempus AI
US88023B1035

NEW YORK, July 31, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Tempus AI, Inc. ("Tempus" or the "Company")(NASDAQ: TEM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encoura...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Wed, 30.07.2025       Tempus AI
US88023B1035

BENSALEM, Pa., July 30, 2025 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Tempus AI, Inc. ("Tempus" or the "Company") (NASDAQ: TEM). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN TEMPUS AI, INC. (TEM), CONTACT THE LAW...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Tue, 29.07.2025       Tempus AI
US88023B1035

SAN DIEGO, July 29, 2025 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of Tempus AI, Inc. (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025, inclusive (the "Class Period"), have until Tuesday, August 12, 2025 to seek appointment as lead plaintiff of the Tempus AI class action lawsu...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Mon, 28.07.2025       Tempus AI
US88023B1035

LOS ANGELES, July 28, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Tempus AI, Inc. ("Tempus" or "the Company") (NASDAQ: TEM) for violations of securities laws. Shareholders who purchased the Company's securities between August 6, 2024, and May 27, 2025, inclusive (the "Class Period"), are encouraged...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Mon, 28.07.2025       Tempus AI
US88023B1035

LOS ANGELES, July 28, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Tempus AI, Inc. ("Tempus" or "the Company") (NASDAQ: TEM) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Se...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Sun, 27.07.2025       Tempus AI
US88023B1035

NEW YORK, July 27, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Tempus AI, Inc. ("Tempus" or the "Company")(NASDAQ: TEM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encoura...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Sat, 26.07.2025       Tempus AI
US88023B1035

NEW ORLEANS, July 25, 2025 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until August 12, 2025 to file lead plaintiff applications in a securities class action lawsuit against Tempus AI, Inc. (NasdaqGS: TEM), if they purchased the Company's shares between August 6, 2024 and May 27, 2025, inc...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Wed, 23.07.2025       Tempus AI
US88023B1035

SAN DIEGO, July 23, 2025 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Tempus AI, Inc. (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025. Tempus purports to be provide Artificial Intelligence ("AI") enabled precision medicine solutions....
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Wed, 23.07.2025       Tempus AI
US88023B1035

LOS ANGELES, July 23, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Tempus AI, Inc. ("Tempus" or the "Company") (NASDAQ: TEM)....
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Tue, 22.07.2025       Tempus AI
US88023B1035

NEW YORK , July 22, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Tempus AI, Inc. ("Tempus" or the "Company")(NASDAQ: TEM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encour...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Tue, 22.07.2025       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the second quarter of 2025 on Friday, August 8, 2025. The company will hold the earnings conference call at 8:00 a.m. ET. The company’s quarterly earnings will be released the same day. The call will f...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Sat, 19.07.2025       Tempus AI
US88023B1035

NEW YORK and NEW ORLEANS, July 18, 2025 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 12, 2025 to file lead plaintiff applications in a securities class action lawsuit against Tempus AI, Inc. (NasdaqGS: TEM), if they purc...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Thu, 17.07.2025       Tempus AI
US88023B1035

LOS ANGELES, July 17, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Tempus AI, Inc. ("Tempus" or the "Company") (NASDAQ: TEM) have opportunity to lead the securities fraud class action lawsuit....
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Thu, 17.07.2025       Tempus AI
US88023B1035

NEW YORK, July 17, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Tempus AI, Inc. ("Tempus" or the "Company")(NASDAQ: TEM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encoura...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Wed, 16.07.2025       Tempus AI
US88023B1035

  BENSALEM, Pa., July 16, 2025 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Tempus AI, Inc. ("Tempus" or the "Company") (NASDAQ: TEM). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN TEMPUS AI, INC. (TEM), CONTACT THE L...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Wed, 16.07.2025       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Tempus ECG-Low EF (ejection fraction) software, which uses AI to identify certain patients who may have a low left v...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Mon, 14.07.2025       Tempus AI
US88023B1035

LOS ANGELES, July 14, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Tempus AI, Inc. ("Tempus" or "the Company") (NASDAQ: TEM) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Se...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Mon, 14.07.2025       Tempus AI
US88023B1035

LOS ANGELES, July 14, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Tempus AI, Inc. ("Tempus" or "the Company") (NASDAQ: TEM) for violations of securities laws. Shareholders who purchased the Company's securities between August 6, 2024, and May 27, 2025, inclusive (the "Class Period"), are encouraged...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink